British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

The UK cost-effectiveness watchdog on Thursday recommended AbbVie's "guided missile" cancer therapy, Elahere, for patients with a hard-to-treat form of ovarian cancer.